Content about Corporate crime

WASHINGTON — The National Consumer League on Wednesday filed a formal complaint with the Federal Trade Commission that called into question advertising and labeling claims made by Glacéau’s Vitaminwater.

The NCL identified print and television advertisements that suggested that Vitaminwater can replace flu shots and prevent illness as “dangerously misleading.”

NEW YORK — Pfizer again has extended the expiration date on its tender offer to buy Bristol, Tenn.-based King Pharmaceuticals to Jan. 28, the drug maker said Friday.

Pfizer announced in October that it would buy King for $3.6 billion, or $14.25 per share. King manufactures branded prescription drugs, including several painkillers.

MADISON, N.J. — Pfizer Consumer Healthcare on Tuesday launched a new consumer promotion campaign featuring television actress Angie Harmon in support of its Children’s Advil brand.

NEW YORK Pfizer officially has made its tender offer to buy King Pharmaceuticals for $3.6 billion, or $14.25 per share, Pfizer said Friday.

The offer constitutes a 40% premium over the closing price of King’s stock on Oct. 11, when Pfizer originally made the offer. King, based in Bristol, Tenn., specializes in pain medications designed to deter misuse and abuse, and Pfizer said the acquisition would enhance its position in the pain-relief market.

The offer expires at midnight on Nov. 19.

NEW YORK Pfizer on Wednesday announced the completion of its acquisition of a privately held drug discovery and clinical development company.

FoldRx now is a wholly owned subsidiary of Pfizer, Pfizer said. FoldRx's portfolio includes clinical and preclinical programs for investigational compounds to treat diseases caused by protein misfolding, which increasingly is recognized as an underlying cause in many chronic degenerative diseases.

The acquisition was announced Sept. 1.

NEEDHAM, Mass. Pfizer is pulling out of a development deal for a potential brain cancer drug, saying it is not a strategic priority, according to the drug's developer Celldex Therapeutics.

Celldex said it will regain full worldwide rights to develop and sell rindopepimut from Pfizer. The drug candidate also is called CDX-110. In May, the company reported positive results form a midstage study on the drug.

Celldex will regain rights to the drug candidate on Nov. 1.

NEW YORK The Food and Drug Administration has approved a prefilled dual-chamber syringe made by Pfizer for treating hemophilia, Pfizer said.

The FDA approved the syringe for administering the drug Xyntha (antihemophilic factor [recombinant]) for hemophilia A. The drug is used to prevent and control bleeding episodes in patients.